Updates are available Correction dated 2025-03-19
Click to view Correction: https://doi.org/10.1038/s41386-025-02087-2
-
Authors
Wengler, Kenneth https://orcid.org/0000-0002-8153-5183
Trujillo, Paula
Cassidy, Clifford M.
Horga, Guillermo
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH117323)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH114965)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 15 April 2024
Revised: 21 June 2024
Accepted: 15 July 2024
First Online: 19 August 2024
Change Date: 19 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41386-025-02087-2
Competing interests
: KW, CMC, and GH are inventors on filed patents for the analysis and use of neuromelanin-sensitive MRI in central nervous system disorders licensed to Terran Biosciences, with no royalties received. GH and PT reported investigator-initiated sponsored research agreements with Terran Biosciences outside the submitted work.
